Candel Therapeutics stock price target raised to $14 by Freedom Capital

Candel Therapeutics received a price-target raise to $14 from Freedom Capital (vs. current $4.63 and analyst range $7–$25) after encouraging CAN-3110 Phase 1b survival data and positive Phase 3 CAN-2409 results presented at SITC/ASTRO that met the primary endpoint and showed a 30% improvement in disease-free survival; the company plans a BLA submission in Q4 2026. Management has secured a $130 million term loan with Trinity (initial $50m draw, 10.25% interest, 36-month interest-only) to fund a planned Q2 2026 Phase III in NSCLC and BLA preparations, and balance-sheet metrics (current ratio ~8.25) suggest near-term liquidity. While the clinical readouts and financing materially de-risk key oncology programs and support upside, rising operating expenses and higher borrowing costs have increased R&D spend and the company’s weighted-average cost of capital, elevating execution and financing risk.

Analysis

Freedom Capital raised its price target on Candel Therapeutics to $14 from $13 and maintained a Buy rating, implying roughly 202% upside from the current $4.63 share price; analyst targets overall range $7–$25, and InvestingPro notes the stock is trading near its fair value. The upgrade follows encouraging CAN-3110 Phase 1b survival data that prompted an increased probability-of-approval estimate and positive Phase III CAN-2409 results presented at SITC/ASTRO and ASTRO where the trial met its primary endpoint and subgroup analyses showed a ~30% improvement in disease-free survival versus placebo.

Candel secured a $130 million term loan facility with Trinity Capital (initial $50m draw, 10.25% interest, 36-month interest-only period with milestone-based tranches) to fund a planned Q2 2026 Phase III in NSCLC and BLA preparations targeting Q4 2026. InvestingPro metrics show a current ratio of ~8.25 and more cash than debt, indicating near-term liquidity, but management has raised its near-term R&D forecast as operating expenses accelerate.

The combination of positive clinical readouts and secured financing materially de-risks program timelines and supports upside, as reflected in reaffirmed Buy ratings (H.C. Wainwright $23 PT). Key risks are execution on milestone-driven tranche availability, elevated borrowing costs that raise WACC, rising cash burn from increased R&D, and the need for commercial adoption assumptions to hold; monitor upcoming readouts and tranche triggers as primary value inflection points.

Key Decisions for Investors

• Consider a tactical, size-limited long position to capture upside from de-risked oncology programs given supportive Phase 1b/Phase 3 data and analyst price targets, but avoid full exposure until milestone-tranche mechanics and continued funding are confirmed
• Monitor cash runway, covenant language and tranche-trigger milestones tied to the $130m Trinity facility and watch for any signs of accelerated cash burn from higher R&D spend before increasing exposure
• Use position sizing or hedges to protect against clinical or financing setbacks given the 10.25% loan, rising operating expenses and higher weighted-average cost of capital
• Reassess the thesis on delivery of the Q2 2026 NSCLC Phase III start and the planned Q4 2026 BLA timeline; materially missed milestones or weaker subgroup/secondary data should prompt a reduction in exposure